Zusammenfassung
Das Prostatakarzinom entwickelt sich schnell zum am häufigsten diagnostizierten Karzinom in der westlichen Welt [71], mit einer stetig wachsenden Inzidenzrate [24, 73] und einer bei der schwarzen Bevölkerung Amerikas doppelt so hohen Mortalitätsrate wie bei der weißen Bevölkerung. Darüber hinaus nimmt der Anteil der männlichen Bevölkerung jenseits des 65. Lj. insbesondere in Nordamerika und in den EG-Ländern weiterhin zu [24]. Prostataerkrankungen wie die benigne Prostatahypertrophie (BPH) oder das Prostatakarzinom werden in wachsendem Maße zu einem schwerwiegenden gesundheitspolitischen Problem. Daher ist es sicherlich an der Zeit, unsere Kenntnisse bezüglich des natürlichen Krankheitsverlaufs der BPH und des Prostatakarzinoms sowie der biologischen Vorgänge, die mit der Pathogenese dieser Krankheiten zusammenhängen, erneut zu überprüfen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Adlercreutz H (1988) Lignans und phytoestrogens: possible preventive role in cancer. In: Rozen P, Horwitz C (eds) Frontiers in gastrointestinal research. Karger, Basle, pp 165–176
Atkin NB, Baker MC (1985) Chromosome study of five cancers of the prostate. Human Genetics 70:359–364
Atkin NB, Baker MC (1985) Chromosome 10 deletion in carcinoma of the prostate. New Engl J Medicine 312:315
Baba S (1982) Epidemiology of cancer of the prostate: analysis of countries of high and low incidence. In: Jacobi GH, Hohenfellner R (eds) Prostate cancer, international perspectives in urology, vol 3. Williams & Wilkins, Baltimore, pp 11–28
Baker SJ, Fearon ER, Nigro JM et al. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221
Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912–915
Blute ML, Zincke H, Farrow GM (1986) Long-term follow up of young patients with stage A adenocarcinoma of the prostate. J Urol 136:840–843
Bookstein Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee WH (1990) Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci 87:7762–7766
Bookstein R, Shew JY, Chen PL, Scully P, Lee WH (1990) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712–715
Bostwick DG, Brawer MK (1987) Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 59:788–794
Bostwick DG (1989) Prostatic intraepithelial neoplasia (PIN). Urology 34 [Suppl]: 16–22
Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Blarney RW, Nicholson RI (1989) Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Brit J Cancer 59:943–947
Bravo R, Frank R, Blundell PA, MacDonald-Bravo H (1987) Cyclin/PCNA is the auxilliary protein of DNA polymerase delta. Nature (Lond) 326:515–520
British Prostate Study Group (1979) Evaluation of plasma hormone concentrations in relation to clinical staging in patients with prostatic cancer. Brit J Urol 51:382–389
Brothman AR, Peehl DM, Patel AM, McNeal JE (1990) Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res 50:3795–3803
Brown DC, Cole D, Gaiter KC, Mason DY (1988) Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki-67. Brit J Cancer 57:178–181
Bussemakers MJG, Isaacs WB, Carter BS, van de Ven W, DeBruyne FMJ, Schalken JA (1991) E-cadherin is a candidate tumor suppressor gene implicated in prostate cancer. J Urol 145:294A
Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA (1987) Enhanced expression of the c-myc protooncogene high-grade human prostate cancers. The Prostate 11:327–337
Buttyan R, Zakeri Z, Lockshin R, Wolgemuth D (1988) Cascade induction of c-fos, c-myc, and heat shock 70 K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol 2:650–657
Callahan R, Campbell G (1989) Mutations in human breast cancers: an overview. J Natl Cancer Inst 81:1780–1786
Cannon L, Bishop DT, Skolnick M, Hunt S, Lyon JL, Smart CR (1982) Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1:47–69
Cantrell BB, deKlerk DP, Eggleston JC, Boitnott JK, Walsh PC (1981) Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol 125:516–520
Carter BS, Ewing CM, Ward SW et al. (1990) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci 87:8751–8755
Carter HB, Coffey DS (1988) Prostate cancer: the magnitude of the problem in the United States. In: Coffey DS, Resnick MI, Dorr FA, Karr JP (eds) A multidisciplinary analysis of controversies in the management of prostatic cancer. Plenum Press, New York, pp 1–7
Cooke DB, Quarmby VE, Mickey DD, Isaacs JT, French FS (1988) Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostate adenocarcinoma system. The Prostate 13:263–272
Curran T, Bravo R, Muller R (1985) Transient induction of c-fos and c-myc is an immediate consequence of growth factor stimulation. Cancer Surv 4:655–681
Ekman P (1989) BPH epidemiology and risk factors. The Prostate 2 [Suppl]:23–31
Epstein JI, Pauli G, Eggleston JC, Walsh PC (1986) Prognosis of untreated stage A prostate carcinoma: a study of 94 cases with extended follow-up. J Urol 136:837–839
Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Dodd JG, Mutusik RJ (1986) Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46:1535–1538
Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H (1984) Growth fractions in malignant non-Hodgkin’s lymphomas as determined in situ with the monoclonal antibody Ki-67. Haematol Oncol 2:365–371
Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Reps 50:125–128
Golimbu M, Schinella R, Morales P, Kurusu S (1978) Differences in pathological characteristics and prognosis of clinical Al and B disease. J Urol 119:618–622
Griffiths K, Davies P, Eaton CL, Harper ME et al. (1987) In: Clark JR (ed) Oxford Reviews of Reproductive Biology, vol 9. Oxford University Press, pp 192–259
Griffiths K, Davies P, Eaton CL, Harper ME, Turkes A, Peeling WB (1991) In: Voigt KD, Knabbe C (eds) Endocrine dependent tumors. Raven, New York, pp 83–130
Haenzel W, Kurihara M (1968) Studies of Japanese migrants. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40:43–68
Harper ME, Glynne-Jones E, Goddard L et al. (1992) Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. The Prostate 20
Harper ME, Goddard L, Wilson DW, Matenhelia SS, Conn IG, Peeling WB, Griffiths K (1992) Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. The Prostate 21:75–84
Harper ME, Wilson DW, Jensen HM, Pierrepoint CG, Griffiths K (1987) Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade. J Steroid Biochem 27:521–524
Helpap B (1989) Do precursor lesions of prostatic carcinoma exist? World J Urol 7:27–33
Huang H-J, Yee J-K, Shew J-Y et al. (1988) Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563–1566
Isaacs JT, Coffey DS (1989) Etiology and disease process of benign prostatic hyperplasia. The Prostate, Suppl 2:33–50
Jain S, Filipe MI, Hall PA, Waseem NH, Lane DA, Levison DA (1991) Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Path 44:655–659
Kastendieck H (1980) Correlations between atypical primary hyperplasia and carcinoma of the prostate. Pathol Res Pract 169:366–387
Katz AE, Benson MC, Wise GJ et al. (1989) Gene activity during the early phase of androgen-stimulated rat prostate regrowth. Cancer Res 49:5889–5894
Klein G (1987) The approaching era of the tumor suppressor genes. Science 238:1539–1545
Knudson AG (1985) Hereditary cancer, oncogenes and anti-oncogenes. Cancer Res 45:1437–1443
Koppe IM, Heranze DR, Shimkin MB (1967) Characteristics of patients with prostatic carcinoma: a control case study on 83 autopsy pairs. J Urol 98:229–233
Kovi J, Mostofi FK (1989) Atypical hyperplasia of prostate. Urology 34 [Suppl]:23–27
Krain LS (1974) Some epidemiologic variables in prostatic carcinoma in California. Preventive Medicine 3:154–159
Lee WH, Bookstein R, Lee EY-HP (1988) Studies on the human retinoblastoma susceptibility gene. J Cellular Biochem 38:213–227
Marx JL (1987) The fos gene as master switch. Science 237:854–856
McNeal JE, Bostwick DG (1986) Intraductal dysplasia: A premalignant lesion of the prostate. Human Pathol 17:64–71
McNeal JE (1978) Origin and evolution of benign prostatic enlargement. Invest Urol 15:340–345
McNeal JE (1981) The zonal anatomy of the prostate. The Prostate 2:35–49
McNeal JE (1975) Structure and pathology of the prostate. In: Goland M (ed) Normal and abnormal growth of the prostate. Thomas, Springfield, pp 55–65
McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA (1986) Patterns of progression in prostate cancer. Lancet 1:60–63
McNeal JE, Price HM, Redwine EA, Freiha FS, Stamey TA (1988) Stage A versus stage B adenocarcinoma of the prostate: morphologic comparison and biologic significance. J Urol 139:61–65
Meikle AW, Smith JA, West DW (1985) Familial factors affecting prostatic cancer risk and plasma sex steroid levels. The Prostate 6:121–128
Miller JG (1988) Diagnosis of stage A prostate cancer in the People’s Republic of China. In: Coffey DS, Resnick MI, Dorr FA, Karr JP (eds) A multidisciplinary analysis of controversies in the management of prostate cancer. Plenum Press, New York, pp 17–24
Morganti G, Gianferrari L, Cresseri A, Arrigoni G, Lovati G (1956) Récherches clinico-statistiques et génétiques sur les néoplasies de la prostate. Acta Genetica Statistica 6:304–305
Mostofi FK, Sesterhehn I, Sobin LH (1980) Histological typing of prostatic tumours. International histological classification of tumours, No 22. Geneva, World Health Organisation
Natt E, Magenis RE, Zimmer J, Mansouri A, Scherer G (1989) Regional assignment of the human loci for uvomorulin and chymotrypsinogen B with the help of two overlapping deletions on the long arm of chromosome 16. Cytogenetics and Cell Genetics 50:145–148
Oomens EHGM, van Steenbrugge GJ, van der Kwast TH, Schroeder FH (1991) Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the proliferative cell fraction of human prostatic carcinoma. J Urol 145:81–85
Oota K, Misu Y (1958) A study of latent carcinoma of the prostate in Japanese. Gann 49:283–293
Partin AW, Isaacs JT, Treiger G, Coffey DS (1988) Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with v-Harvey-ras oncogene. Cancer Res 48:6050–6053
Peehl DM, Wehner N, Stamey TA (1987) Activated Ki-ras oncogene in human prostatic adenocarcinoma. The Prostate 10:281–289
Phillips MEA, Ferro MA, Smith PJB, Davies P (1987) Intranuclear androgen receptor deployment and protogene expression in human diseased prostate. Urol Int 42:115–119
Rich AR (1935) On frequency of occurrence of occult carcinoma of prostate. J Urol 33:215–223
Rijnders AWM, van der Korput JAGM, van Steenbrugge GJ, Romijn JC, Trapman J (1985) Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 132:548–554
Sager R (1989) Tumor suppressor genes: the puzzle and the promise. Science 246:1406–1412
Silverberg E, Lubera JA (1989) Cancer Statistics. Cancer 39:3–20
Skeet RG (1976) Epidemiology of urological tumours. In: Williams DI, Chisholm GD (eds) Scientific foundations of urology, vol IL Heinemann, London, pp 199–211
Sondik E (1988) Incidence, survival and mortality trends in prostate cancer in the United States. In: Coffey DS, Resnick MI, Dorr FA, Karr JP (eds) A multidisciplinary analysis of controversies in the management of prostatic cancer. Plenum Press, New York, pp 9–16
Stamey TA (1982) Cancer of the prostate. In: Stamey TA (ed) Monographs in urology 3:1–10
Steinberg GS, Carter BS, Beaty TH, Childs B, Walsh PC (1990) Family history and the risk of prostate cancer. The Prostate 17:337–347
Thompson TC, Southgate J, Kitchner G, Land H (1989) Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56:917–930
Treiger B, Isaacs JT (1988) Expression of a v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. J Urol 140:1580–1586
Tsai Y, Nichols P, Hiti A, Williams Z, Skinner D, Jones P (1990) Allelic losses of chromosomes 9, 11 and 17 in human bladder cancer. Cancer Res 50:44–47
Turkes A, Nott JP, Griffiths K (1991) Prostate-specific antigen: problems in analysis. Eur J Cancer 27:650–652
Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R (1989) Allelotype of colorectal cancinomas. Science 244:207–211
Weinberg RA (1989) Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49:3713–3721
Weisz A, Bresciani F (1988) Estrogen induces expression of c-fos and c-myc protoonco-genes in rat uterus. Molecular Endocrin 2:816–824
Weisz A, Rosales R (1990) Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Research 18:5097–5106
Weisz A, Cicatiello L, Persico E, Scalona M, Bresciani F (1990) Estrogen stimulates transcription of c-jun protooncogene. Molecular Endocrin 4:1041–1050
Whitmore WF (1986) Stage A prostatatic cancer. J Urol 136:883
Woolf CM (1960) An investigation of the familial aspects of carcinoma of the prostate. Cancer 13:739–744
Wynder EL, Mabuchi K, Whitmore WF (1971) Epidemiology of cancer of the prostate. Cancer 28:344–360
Yokota J, Wada M, Shimosato Y, Terado M, Sigimura T (1987) Loss of heterozygosity on chromosome 3, 13 and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci 84:9252–9256
Yu CC-W, Hall PA, Fletcher CDH, Camplejohn R, Waseem NH, Lane DP, Levison DA (1990) Immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen may be a good predictor of prognosis in haemangiopericytomas. J Path 161:342a
Yunis Y (1983) Chromosomal basis of neoplasia. Science 221:335–340
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Harper, M.E., Eaton, C.L., Turkes, A., Griffiths, K. (1995). Andere für das Prostata-Screening interessante Marker. In: Faul, P., Altwein, J.E. (eds) Screening des Prostatakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78318-0_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-78318-0_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78319-7
Online ISBN: 978-3-642-78318-0
eBook Packages: Springer Book Archive